Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
NCT01399840
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
1. 18 years of age or older.
2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
3. Arm 1 AML/MDS: Must have available tissue
4. Arm 2 CLL/MCL: Must have available tissue
5. Have adequate organ function as defined below:
1. Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 X upper limit of normal (ULN);
2. Total serum bilirubin ≤ 1.5 X ULN;
6. Able to take oral medications
7. Recovered from acute toxicity of prior treatment
8. Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
9. If sexually active, must be willing to use an acceptable method of contraception during therapy and for 30 days after the last dose of BMN 673.
10. If female of childbearing potential, must have a negative serum pregnancy test at screening and be willing to have additional pregnancy tests during the study.
11. Willing and able to comply with all study procedures.
1. Acute promyelocytic leukemia, APL [AML with t(15;17)(q22;q12), PML-RARA and variants].
2. Disease-specific exclusion criteria:
a. AML: i. Marrow cellularity < 25% ii. Circulating blasts > 50,000/mm3 b. MCL and
CLL: i. Platelet count < 50,000/mm3 ii. Neutrophil count < 1000/mm3
3. Autologous bone marrow transplant < 6 months before Cycle 1 Day 1
4. Prior allogeneic bone marrow transplant < 6 months before Cycle 1 Day 1 and/or with
the presence of graft versus host disease (GVHD)
5. Prior treatment:
1. AML: anti-leukemia treatment within 14 days before Cycle 1 Day 1; hydroxyurea
treatment within 7 days before Cycle 1 Day 1.
2. CLL, MCL or MDS: anti-lymphoma/leukemia treatment within 28 days before Cycle 1
Day 1;
6. CLL/MCL patients who have received transfusion, hematopoietic growth factors within 7
days before Cycle 1 Day 1.
7. Symptomatic central nervous system (CNS) involvement.
8. Known to have human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or
hepatitis B virus (HBV).
9. Major surgery within 28 days before Cycle 1, Day 1.
10. Active peptic ulcer disease.
11. Active gastrointestinal tract disease with malabsorption syndrome.
12. Requirement for IV alimentation.
13. Prior surgical procedures affecting absorption.
14. Uncontrolled inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
15. Myocardial infarction within 6 months before Cycle 1 Day 1, symptomatic congestive
heart failure (New York Heart Association > class II), unstable angina, or unstable
cardiac arrhythmia requiring medication.
16. Breastfeeding at screening or planning to become pregnant (self or partner) at any
time during study participation.
17. Use of any investigational product or investigational medical device within 28 days
before Cycle 1, Day 1.
18. Concurrent disease or condition that would interfere with study participation or
safety, such as:
1. CLL/MCL patients with active, clinically significant infection requiring the use
of parenteral anti-microbial agents, or grade > 2 infection by NCI CTCAE (v4.03)
within 14 days before Cycle 1, Day 1(AML/MDS patients with controlled infection
are eligible for the study with no specific time requirement prior to Cycle 1,
Day 1);
2. Clinically significant bleeding diathesis or coagulopathy, including known
platelet function disorders;
3. Non-healing wound, ulcer, or bone fracture.
19. Patients who have received prior treatment with a PARP inhibitor are not eligible for
Part 2 of the study (expansion), but are eligible for Part 1 (dose escalation) of the
study.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Indianapolis, Indiana
- Seattle, Washington
- Madison, Wisconsin
- London,
- London,
- Manchester,
- Newcastle upon Tyne,
Descriptive Information | |||||
---|---|---|---|---|---|
Brief Title ICMJE | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies | ||||
Official Title ICMJE | Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies | ||||
Brief Summary | This is a two-arm, open-label study to determine the maximum tolerated dose (MTD) and assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). Arm 1 will enroll patients with either AML or MDS; Arm 2 will enroll patients with either CLL or MCL. | ||||
Detailed Description | Not Provided | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 | ||||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||
Condition ICMJE |
| ||||
Intervention ICMJE | Drug: BMN 673
Oral capsule with multiple dosage forms given once daily | ||||
Study Arms ICMJE |
| ||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Actual Enrollment ICMJE | 33 | ||||
Original Estimated Enrollment ICMJE | 80 | ||||
Actual Study Completion Date ICMJE | May 31, 2014 | ||||
Actual Primary Completion Date | March 31, 2014 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||
Sex/Gender ICMJE |
| ||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | United Kingdom, United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT01399840 | ||||
Other Study ID Numbers ICMJE | PRP-002 2010-023964-42 ( EudraCT Number ) C3441022 ( Other Identifier: Alias Study Number ) | ||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product | Not Provided | ||||
IPD Sharing Statement ICMJE |
| ||||
Responsible Party | Pfizer | ||||
Study Sponsor ICMJE | Pfizer | ||||
Collaborators ICMJE | Medivation, Inc. | ||||
Investigators ICMJE |
| ||||
PRS Account | Pfizer | ||||
Verification Date | September 2017 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |